Back to Search
Start Over
Pharmacokinetic testing of a first-generation cabotegravir prodrug in rhesus macaques
- Source :
- AIDS. 33:585-588
- Publication Year :
- 2019
- Publisher :
- Ovid Technologies (Wolters Kluwer Health), 2019.
-
Abstract
- Long-acting antiretrovirals can improve therapy and prevention for HIV-1 infection. Current long-acting cabotegravir (CAB LAP) can be administered every other month. Previously, we demonstrated that a myristoylated CAB prodrug encased in poloxamer 407 provided extended plasma drug concentrations. We now demonstrate that this first-generation nanoformulated prodrug can sustain plasma CAB concentrations above the protein-adjusted 90% inhibitory concentration for 4 months in rhesus macaques. A 2.5-fold extension in CAB half-life and a 1.6-fold increase in area under the concentration-time curve were observed compared with CAB LAP.
- Subjects :
- 0301 basic medicine
Drug
Anti-HIV Agents
Pyridones
media_common.quotation_subject
Immunology
Poloxamer
Pharmacology
Article
Plasma
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Cabotegravir
Pharmacokinetics
Animals
Immunology and Allergy
Medicine
Prodrugs
030212 general & internal medicine
media_common
Drug Carriers
business.industry
Extramural
fungi
food and beverages
Prodrug
Macaca mulatta
First generation
030104 developmental biology
Infectious Diseases
chemistry
Delayed-Action Preparations
Plasma chemistry
Poloxamer 407
business
Half-Life
medicine.drug
Subjects
Details
- ISSN :
- 02699370
- Volume :
- 33
- Database :
- OpenAIRE
- Journal :
- AIDS
- Accession number :
- edsair.doi.dedup.....caeeca7c7974dce4c33af773850aced6